CLINICAL TRIALS PROFILE FOR HYALURONIDASE
✉ Email this page to a colleague
Biosimilar Clinical Trials for hyaluronidase
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT06100874 ↗ | A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) | Recruiting | Gilead Sciences | Phase 2 | 2023-11-20 | This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: - Sacituzumab govitecan (a type of antibody-drug conjugate) - Trastuzumab (Herceptin) (a type of monoclonal antibody) - Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody) - Trastuzumab biosimilar drug |
| NCT06100874 ↗ | A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) | Recruiting | Adrienne G. Waks | Phase 2 | 2023-11-20 | This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: - Sacituzumab govitecan (a type of antibody-drug conjugate) - Trastuzumab (Herceptin) (a type of monoclonal antibody) - Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody) - Trastuzumab biosimilar drug |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for hyaluronidase
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000493 ↗ | Multicenter Investigation of Limitation of Infarct Size (MILIS) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1977-09-01 | To assess the ability of two separate therapeutic interventions, propranolol and hyaluronidase, to limit the ultimate size of an acute myocardial infarction. A secondary objective was to assess the influence of these therapies upon ventricular function and morbidity following myocardial infarction. |
| NCT00198419 ↗ | Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) | Completed | Bausch & Lomb Incorporated | Phase 1 | 2004-03-01 | The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to 10% hypersensitivity response was considered acceptable. |
| NCT00198458 ↗ | Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) | Completed | Bausch & Lomb Incorporated | Phase 1 | 2004-07-01 | The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to a 10% hypersensitivity response was considered acceptable. |
| NCT00198471 ↗ | Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment | Completed | Bausch & Lomb Incorporated | Phase 2 | 2005-07-01 | The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for hyaluronidase
Condition Name
Clinical Trial Locations for hyaluronidase
Trials by Country
Clinical Trial Progress for hyaluronidase
Clinical Trial Phase
Clinical Trial Sponsors for hyaluronidase
Sponsor Name
